Optimizing the use of 17P in pregnant managed Medicaid members

Managed Care

Volumn 17, Issue 1, 2008, Pages 47-52

  Mason, Mary V ^a,b   House, Kara M ^a   Linehan, Janice ^a   Speers, Carol A ^a   Joseph, Lisa M ^a   Littlejohn, Ray ^c  

^a CENTENE CORPORATION   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Quest Alliance Inc

Author keywords

17P; Managed Medicaid; NICU; Preterm birth

Indexed keywords

17 HYDROXYPREGNENOLONE;

ARTICLE; COMPARATIVE STUDY; FEMALE; HEALTH INSURANCE; HUMAN; MEDICAID; NEWBORN INTENSIVE CARE; PREGNANCY; UNITED STATES; UTILIZATION REVIEW;

17-ALPHA-HYDROXYPREGNENOLONE; FEMALE; HUMANS; INTENSIVE CARE, NEONATAL; MANAGED CARE PROGRAMS; MEDICAID; PREGNANCY; UNITED STATES;

EID: 40649111353     PISSN: 10623388     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Article

References (14)

1. ACOG (American College of Obstetrics and Gynecology). Progesterone recommended in certain high-risk pregnancies to help prevent preterm birth. Press release. Oct. 31, 2003.
2. Katz A, Lancet M, Skornik J, et al. Teratogenicity of progestogens given during the first trimester of pregnancy. Obstet Gynecol. 1985;65(6):775-780.
3. Mardi of Dimes. "Drug to Prevent Preterm Birth Needs Prompt FDA Approval." Press release, Aug. 26, 2006.
4. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2002. Natl Vital Stat Rep. 2003;52(10):1-113.
5. Martin JA, Hamilton BE, Sutton PD, et al. Births: final data for 2003. Natl Vital Stat Rep. 2005;54(2):1-116.
6. Mason MV, House KM, et al. 17 alpha-hydroxyprogesterone caproate usage in a Medicaid managed care plan and reduction in NICU days. Managed Care 2005;14(10):58-63.
7. Meis PJ, Klebanoff M, Thorn E, et al. Prevention of recurrent preterm delivery by 17-alpha hydroxyprogesterone caproate. N Engl J Med 2003;349(13):1299.
8. Mercer BM, Goldenberg RI, Moawad AH, et al. The preterm prediction study: effect of gestatioanal age and cause of preterm birth on subsequent obstetric outcome. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol. 1999;18(5 Pt 1):1216-1221.
9. Michaelis J, Michaelis H, Gluck E, Keller S. Prospective studies of suspected association between certain drugs administered in early pregnancy and congenital malformations. Teratology. 1983;27:57-64.
10. Petrini JR, Callaghan WM, Klebanoff M, et al. Estiniated effect of 17-alpha hydroxyprogesterone caproate on preterm birth in the United States. Obstet Gynecol. 2005;105(2):267-272.
11. Raman-Wilms L, Tseng AL, Wighardt S, et al. Fetal genital effects of first trimester sex hormone exposure: a meta-analysis. Obstet Gynecol. 1995;85(1):141-149.
12. Anonymous. Reprotox. 1997, vol:92. Micromedix Inc. Available at: «
13. Resseguie LJ, Hick JF, Bruen JA, et al. Congenital malformations among offspring exposed in utero to progestins. Olmsted County, Minn., 1936-1974. Fertil Steril. 1985;43(4):514-519.
14. Varma T, Morsman J. Evaluation of the use of hydroxyprogesterone hexanate in early pregnancy. Int Gynecol Obstet. 1982;20:13-17.